Eledon Total Current Assets vs Other Current Assets Analysis
ELDN Stock | USD 3.02 0.22 7.86% |
Eledon Pharmaceuticals financial indicator trend analysis is much more than just examining Eledon Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eledon Pharmaceuticals is a good investment. Please check the relationship between Eledon Pharmaceuticals Total Current Assets and its Other Current Assets accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.
Total Current Assets vs Other Current Assets
Total Current Assets vs Other Current Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eledon Pharmaceuticals Total Current Assets account and Other Current Assets. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Eledon Pharmaceuticals' Total Current Assets and Other Current Assets is 0.44. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Other Current Assets in the same time period over historical financial statements of Eledon Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Eledon Pharmaceuticals' Total Current Assets and Other Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Eledon Pharmaceuticals are associated (or correlated) with its Other Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Assets has no effect on the direction of Total Current Assets i.e., Eledon Pharmaceuticals' Total Current Assets and Other Current Assets go up and down completely randomly.
Correlation Coefficient | 0.44 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Other Current Assets
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.Most indicators from Eledon Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eledon Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.Eledon Pharmaceuticals reported last year Tax Provision of (579,000). As of the 17th of May 2024, Enterprise Value is likely to grow to about 74.2 M, while Selling General Administrative is likely to drop about 10.4 M.
Eledon Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Eledon Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eledon Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 10.9M | 197.2M | 170.5M | 92.8M | 125.9M | 81.1M | |
Other Current Liab | 813K | 973K | 2.2M | 3.9M | 2.5M | 2.2M | |
Total Current Liabilities | 1.3M | 2.5M | 4.4M | 6.5M | 3.9M | 3.7M | |
Total Stockholder Equity | 9.5M | 190.6M | 164.0M | 84.2M | 83.4M | 60.7M | |
Property Plant And Equipment Net | 321K | 138K | 768K | 739K | 365K | 278.2K | |
Net Debt | (8.5M) | (114.1M) | (84.1M) | (55.7M) | (4.2M) | (4.4M) | |
Retained Earnings | (57.6M) | (80.4M) | (114.9M) | (202.9M) | (243.2M) | (231.0M) | |
Accounts Payable | 329K | 1.4M | 1.8M | 2.2M | 967K | 1.0M | |
Cash | 8.8M | 114.2M | 84.8M | 56.4M | 4.6M | 4.4M | |
Non Current Assets Total | 960K | 81.6M | 82.2M | 33.3M | 69.8M | 73.3M | |
Non Currrent Assets Other | 639K | 383K | 400K | 150K | 186K | 309.2K | |
Cash And Short Term Investments | 8.8M | 114.2M | 84.8M | 56.4M | 51.1M | 53.7M | |
Common Stock Shares Outstanding | 655.5K | 1.5M | 14.8M | 14.3M | 24.6M | 25.9M | |
Liabilities And Stockholders Equity | 10.9M | 197.2M | 170.5M | 92.8M | 125.9M | 81.1M | |
Non Current Liabilities Total | 144K | 4.1M | 2.2M | 2.1M | 38.6M | 40.5M | |
Other Current Assets | 54K | 38K | 3.5M | 3.1M | 5.0M | 5.3M | |
Other Stockholder Equity | 67.0M | 271.0M | 278.9M | 287.0M | 326.6M | 166.9M | |
Total Liab | 1.5M | 6.6M | 6.6M | 8.6M | 42.5M | 44.6M | |
Property Plant And Equipment Gross | 321K | 138K | 768K | 739K | 365K | 278.2K | |
Total Current Assets | 10.0M | 115.6M | 88.3M | 59.5M | 56.1M | 56.0M | |
Common Stock Total Equity | 7K | 9K | 13K | 15K | 13.5K | 12.8K | |
Common Stock | 9K | 13K | 15K | 14K | 24K | 13.1K | |
Net Tangible Assets | 12.6M | 9.5M | 109.6M | 83.0M | 95.4M | 100.2M | |
Property Plant Equipment | 14K | 321K | 138K | 768K | 883.2K | 927.4K | |
Net Invested Capital | 9.5M | 190.6M | 164.0M | 84.2M | 83.4M | 88.9M | |
Net Working Capital | 8.6M | 113.1M | 83.9M | 53.0M | 52.2M | 53.5M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.Note that the Eledon Pharmaceuticals information on this page should be used as a complementary analysis to other Eledon Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Eledon Stock analysis
When running Eledon Pharmaceuticals' price analysis, check to measure Eledon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eledon Pharmaceuticals is operating at the current time. Most of Eledon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eledon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eledon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eledon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is Eledon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Return On Assets (0.30) | Return On Equity (0.48) |
The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.